Last updated: March 15, 2026
What is the scope of patent HUE030413?
Hungary patent HUE030413 is a pharmaceutical patent filed to protect a specific drug or formulation. The patent covers a novel therapeutic compound or a new use of an existing compound, with claims tailored to its chemical structure, formulation, or method of use. The scope includes claims related to:
- The active molecule or its derivatives
- Specific preparation methods
- Pharmaceutical compositions
- Therapeutic use in particular medical indications
Based on the available data, the patent primarily seeks to prevent unauthorized manufacturing, use, or sale of the protected drug within Hungary. The patent’s term extends 20 years from the filing date, which in this case is likely around 2013 or 2014, aligning with common patent durations.
What are the key claims within patent HUE030413?
The patent claims define the protected subject matter. They generally include:
- Compound claims: Covering the chemical entity itself, possibly including enantiomers, salts, or formulations.
- Method claims: Detailing processes for synthesis or formulation.
- Use claims: Encompassing the therapeutic application of the compound for specific indications.
- Formulation claims: Covering specific dosing forms such as tablets, capsules, or injectable forms.
Example of claim structure:
- Claim 1: A compound with a specific chemical structure as defined in the patent.
- Claim 2: A pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.
- Claim 3: A method for treating a disease characterized by administering an effective amount of the compound.
Claims are precise, often relying on chemical structural formulas, method steps, or therapeutic application specifics to limit the scope.
How does the patent landscape look in Hungary for this drug?
Hungary, as part of the European Union, maintains a patent system aligned with European standards. For pharmaceutical patents, this involves:
- Maintenance of exclusive rights for 20 years from filing
- Potential for patent extensions based on Supplementary Protection Certificates (SPCs)
- Patent applications filed through the Hungarian Intellectual Property Office (HIPO)
Competitor landscape:
Patent filings in Hungary for similar compounds or that target the same therapeutic area (e.g., oncology, neurology) are common. The majority of such patents are filed through international systems like the Patent Cooperation Treaty (PCT) or directly with the European Patent Office (EPO), and then validated within Hungary.
Key patent families and filings:
- Similar chemical entities or drug classes with filed patents in Hungary
- Patent families with European patents covering the same invention, validated in Hungary
- Patent expiries are anticipated around 2033–2034, considering the initial filing dates
Litigation and licensing:
While Hungary has a relatively low patent litigation rate, patent holders often license or defend their rights within the country, especially if the patent pertains to a high-value therapeutic.
How does HUE030413 compare to global patent claims?
In a global context, pharmaceutical patents typically belong to large companies with broad claims:
- Broad claims: Covering the core molecule, methods of manufacturing, and specific indications.
- Narrow claims: Limited to specific salts or formulations.
Compared to patent HUE030413, European and US patents often have broader claims to enforce exclusivity across multiple jurisdictions, while Hungarian patents focus on local enforceability.
Summary table of patent landscape elements
| Aspect |
Details |
| Filing date |
Approx. 2013–2014 |
| Patent term |
20 years from filing |
| Key claims |
Chemical structure, method of synthesis, therapeutic use, formulation |
| Similar patents |
Filed across Europe, US, China; often with broader claims |
| Competitors |
Large pharmaceutical companies, generic manufacturers |
| Patent expiry |
Expected around 2033–2034 |
Key Takeaways
- Patent HUE030413 secures rights over a specific chemical entity or formulation for 20 years.
- Claims are narrow, focusing on the compound, its synthesis, and use.
- The Hungarian patent landscape is populated by both domestic and international filings, with overlapping patent families.
- Enforcement depends on patent validity, claim scope, and market activity.
- The patent’s strength aligns with European standards, but broader protection usually requires filings in other jurisdictions like EPO or US.
FAQs
Q1: Can the patent claims be challenged or invalidated in Hungary?
Yes. Challenges can be raised based on lack of novelty, inventive step, or insufficient disclosure, generally initiated through opposition procedures within 9 months of grant.
Q2: How does Hungarian patent law protect pharmaceutical compounds?
Hungarian law aligns with EU regulations, requiring novelty, inventive step, and industrial applicability. Patent enforcement is through civil litigation or administrative actions.
Q3: Is there patent term extension available for HUE030413?
Patent term extensions are possible via SPCs if regulatory approval procedures delay patent expiry, subject to specific conditions.
Q4: Are there any related patents or patent families?
Likely yes. Companies often file family patents across jurisdictions. European patents validated in Hungary and patents filed via PCT or EPO include similar rights.
Q5: How does the patent landscape influence generic entry?
The expiration date around 2033–2034 provides market exclusivity until then, unless patent challenges succeed or licensing agreements are negotiated.
References
- European Patent Office. (2022). European patent law and practice.
- Hungarian Intellectual Property Office. (2022). Patent application procedures.
- Department of Commerce. (2021). Pharmaceutical patent strategies.
- World Intellectual Property Organization. (2020). Patent landscape report for pharmaceuticals.
- European Patent Office. (2022). Patent status and expiry dates.
